{ "schema_version": "tryding-agent-episode.v1", "episode_id": "20261009_TEVA_MIDDAY", "episode_url": "https://trydingday.com/data/agents/v1/episodes/20261009_TEVA_MIDDAY.json", "public_page_url": "https://trydingday.com/coverage/teva/2026-10-09/midday/", "published_at": "2026-10-09T18:36:52.971242Z", "updated_at": "2026-11-02T16:16:30.959227Z", "lifecycle": { "tracking_status": "open", "active_for_tracking": true, "stage": "tracking" }, "instrument": { "type": "equity", "symbol": "TEVA", "exchange": "NYSE", "name": "Teva Pharmaceutical Industries Limited" }, "technical_reference": { "status": "ok", "reference_price": 41.58, "model_downside_reference": 39.72, "model_upside_scenario_1": 43.44, "model_upside_scenario_2": 45.3, "atr_14": 1.24, "method": "reference_price_plus_minus_atr14" }, "public_content": { "date": "October 9, 2026", "generated_at": "2026-10-09T18:36:52.971242Z", "original_published_at": null, "session_tag": "midday", "label": "Market coverage", "try_label": "Try of the Day", "public_status": "Try of the Day", "why_today": "Within the three evidence-backed cases supplied for this review, TEVA remains the most defensible conditional 15-session thesis. This comparison does not establish how TEVA ranks against alternatives for which comparable evidence was not supplied.", "entry_reasoning": "Panel thesis: The reported FDA approval of Weltruza, together with TEVA's positive relative performance and constructive captured tape, supports a testable follow-through thesis over the next 15 trading sessions. The packet does not establish launch access, uptake or revenue contribution. Invalidation boundary: The thesis weakens if an issuer or regulator source does not confirm the reported approval, or if later company disclosures show limited access or uptake while TEVA's relative strength reverses.", "reference_price": 41.58, "scanner": { "price": 41.58, "reference": 41.58, "score": null, "score_version": "legacy research", "change": 5.99, "volume": 8891320.0, "average_volume": 5300579.0, "volume_ratio": 1.68, "rsi": 59.19, "ema_trend": "39.76 > 39.13 > 37.58", "position_52w": 99.0, "atr_14": 1.24, "vwap": 41.34, "vwap_state": "above", "vwap_distance_pct": 0.58, "vwap_reading": { "price": 41.34, "state": "above", "distance_pct": 0.58 }, "range_position": 0.779, "gap_pct": 0.0, "relative_strength": { "excess_pct": 5.47, "index": "SPY", "index_chg_pct": 0.52, "status": "normal" }, "volume_percentile": { "median_vol": 4849300, "percentile": 98.5, "status": "exceptional", "today_vol": 8891320 }, "extension": { "atr": 1.24, "dist_atr": 1.98, "ema_ref": 39.13, "status": "healthy" }, "atr_move_signal": { "atr_pct": 2.98, "status": "strong", "z": 2.01 }, "sector_breadth": null, "sentiment": null, "sentiment_score": null, "earnings_warning": { "days_away": null, "earnings_date": null, "has_earnings_soon": false, "status": "clear" }, "options_snapshot": null, "extended_hours": { "ext_pct": null, "market_state": "REGULAR", "phase": "regular", "post_market_pct": null, "pre_market_pct": null, "status": "none" }, "coiled_spring": { "component_count": 0, "components": {}, "count": 0, "detector_version": "coiled-compression-ohlc.v1", "reason": "coiled_ohlc_detector_runs_on_research_and_known_ticker_rails", "schema_version": "coiled-features.v2", "status": "not_evaluated" }, "short_pct_float": 2.71, "days_to_cover": 57.43, "catalyst": "Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript", "sector": "Healthcare", "exchange": "NYSE", "sec_signal": null }, "levels": { "reference": 41.58, "downside": 39.72, "upside_1": 43.44, "upside_2": 45.3 }, "review": { "score": null, "status": "Try Of The Day", "summary": "Within the three evidence-backed cases supplied for this review, TEVA remains the most defensible conditional 15-session thesis. This comparison does not establish how TEVA ranks against alternatives for which comparable evidence was not supplied.", "views": [ { "name": "Nate Brooks", "role": "market structure and timing analyst", "icon": "๐Ÿ“ˆ", "view": "Start with the day, not one ticker. The supplied snapshot has the broad benchmarks higher and volatility lower, but yields and the dollar edged up. AP also described rising U.S. stocks alongside unsettled oil and yields. Constructive, yes; relaxed, no.", "reasoning": "I support keeping TEVA as Try of the Day within this three-case comparison. The tape and 20-session relative return still beat the alternatives shown; nothing in this correction adds evidence about the wider candidate set." }, { "name": "Priya Nandakumar", "role": "institutional risk and execution manager", "icon": "๐Ÿ›ก๏ธ", "view": "Oil is still being pushed around by Iran-related uncertainty, and the fresh report puts one-year inflation expectations at 4.7%, up from 4.6% a month earlier. That can keep pressure on rates. A green index snapshot does not make the next fifteen sessions friction-free.", "reasoning": "The narrower comparison matters. It limits how broadly we can state the result, so I accept a larger unresolved share in the confidence balance. It does not erase the evidence that puts TEVA ahead of the two cases actually supplied." }, { "name": "Kenji Osei", "role": "AI Systems & Market Data Integrity Analyst", "icon": "๐Ÿง ", "view": "The breadth proxy was complete for its frozen 300-name universe, but that is still a subset and the end-of-day layer is absent. It supports a limited reading of the session; it cannot certify participation across the whole market.", "reasoning": "Then the correction is explicit: compare all three supplied cases, preserve TEVA's identity and thesis, and tell readers the comparison is bounded. We cannot truthfully supply the missing rows under the no-addition instruction." }, { "name": "Marcus Feld", "role": "information, fundamentals and catalyst analyst", "icon": "๐ŸฆŠ", "view": "TEVA has the most specific product mechanism in this group: trusted reporting says the FDA approved Weltruza, a once-monthly schizophrenia injection. The report is not a direct FDA or company notice, and nothing here shows launch uptake. That distinction stays in the thesis.", "reasoning": "Within those three, TEVA still has the clearest combination of a specific reported product event and relative strength. That is the same decision, not a new selection. The public wording now makes the three-case boundary explicit." }, { "name": "Elena Vartanyan", "role": "independent statistical auditor", "icon": "๐ŸŽฏ", "view": "TEVA's session-15 return estimate is 0.519, barely above even. The model's more adverse p10 maximum-excursion estimate is -16.82% from entry; that is a possible deep dip before the horizon ends, not a forecast of the final return. The prepared SEC inputs are not point-in-time validated. I see a useful Raw Try, but I do not support Try of the Day without direct confirmation.", "reasoning": "The model estimates positive returns of 0.544, 0.558 and 0.519 at sessions 3, 8 and 15. At session 15, the modeled adverse excursion has a -16.820437% p10 and -5.579007% p50. That excursion is the deepest drop from entry within the horizon, not the final return; the estimates remain context, and the prepared SEC inputs are not point-in-time validated. I retain my Raw Try dissent." } ], "conviction": { "status_phrase": "recorded", "basis": "TEVA remains ahead of HUM and DNA on the supplied event-and-tape evidence; the auditor is right that this three-case comparison does not cover a broader set of alternatives, while source confirmation and uptake remain open.", "risk": "", "resolution_pct": 55.0, "counter_case_pct": 25.0, "unresolved_pct": 20.0 }, "context_roundtable": { "mode": "coffee", "status": "complete", "consulted_voice_ids": [ "elena", "marcus", "kenji", "priya", "nate" ], "summary": "The supplied day context mixes growth, wage and price signals with a supportive but time-bounded market snapshot. Intraday breadth looked constructive, though end-of-day breadth was unavailable; survey headlines lacked readings, and geopolitical or technology announcements did not establish market effects.", "long_read": "The macro cut offers several different measures rather than a single inflation or growth verdict. Atlanta Fed GDPNow placed its Q3 2026 nowcast at 3.6%, while its September Wage Growth Tracker was reported at 3.9%; the headline characterized the tracker as easing, but the cut gives no prior reading or exact change. OECD reported August energy inflation at 13.6% and separately said food inflation eased, without supplying a food figure here. August U.S. consumer credit was reported higher, but without a value. The Federal Reserve released its 2025 Survey of Consumer Finances, and October University of Michigan consumer-sentiment and inflation-expectations items were listed without their readings. The IMF highlighted targeted transfers as more cost-effective than broad subsidies, but the supplied summary contains no effect size or study detail.\n\nMarket observations are tied to their capture times. The shared market snapshot was complete across its seven rows at 2026-10-09 16:54 UTC. It recorded changes of +0.58% for the S&P 500, +0.48% for the Nasdaq 100, and +0.44% for the Russell 2000. The VIX level was 14.86, with a โˆ’3.57% change from 15.41. The 10-year Treasury yield level was 5.253%, up 2.20 basis points from 5.231%; DXY was 102.316, up 0.17%. Gold was quoted at $4,215.30 with a +1.40% change, while WTI was $91.15 with a โˆ’0.37% change. A separate fresh intraday breadth proxy at 16:36 UTC showed more advancers than decliners across its covered universe; the end-of-day breadth layer was unavailable. These are dated observations, not a full-close account or a candidate score.\n\nThe Reuters item described the preceding U.S. session as lower for the S&P 500 and Nasdaq while crude rose and semiconductors slumped. The later intraday snapshot had the broad benchmarks higher and WTI lower, but different timestamps do not establish what caused either move. The Treasury action targeting remnants of Iran's shadow fleet is a geopolitical development, not evidence of a measured supply disruption. Anthropic's announcement of a cyber program for critical-infrastructure defense adds a technology and security theme, but the cut supplies no adoption, spending, or earnings outcome.", "transcript": [ { "speaker_id": "elena", "text": "The growth figures are useful orientation, but GDPNow is a nowcast: a model estimate of current-quarter growth before the official GDP release. Atlanta Fed's Q3 estimate was 3.6%, so it frames the outlook while remaining revisable. Its September wage tracker was 3.9%; that is a wage-growth reading, not an inflation rate.", "source_urls": [ "https://x.com/AtlantaFed/status/2108239231348855087", "https://x.com/AtlantaFed/status/2108244536119918881" ] }, { "speaker_id": "marcus", "text": "That distinction matters for the price headlines too. OECD reported August energy inflation at 13.6%, while its separate food-inflation item said food inflation eased but gave no figure in this cut. Those signals differ by category; they do not establish that overall household prices eased.", "source_urls": [ "https://x.com/OECD/status/2108286722488361066", "https://x.com/OECD/status/2108543049479463355" ] }, { "speaker_id": "priya", "text": "The IMF note says targeted transfers are more cost-effective than broad subsidies. That is a policy-design point about directing support; without the underlying estimates here, we cannot attach a dollar amount or infer a measured effect on households.", "source_urls": [ "https://x.com/IMFNews/status/2108125420768157800" ] }, { "speaker_id": "nate", "text": "At the 16:54 UTC snapshot, the S&P 500 changed +0.58%, the Nasdaq 100 +0.48%, and the Russell 2000 +0.44%. The VIX, an options-based gauge of expected near-term market swings, stood at 14.86; its exact change was โˆ’3.57% from 15.41. That reads as a calmer, positive intraday market snapshot, not a full-day close." }, { "speaker_id": "kenji", "text": "Breadth asks whether rising shares extend beyond a few index leaders. The fresh intraday proxy showed advancers outnumbering decliners, which supports broader participation at that capture time. But the end-of-day breadth layer was unavailable, so we cannot say that this reading held through the close." }, { "speaker_id": "marcus", "text": "Reuters summarized the preceding U.S. session as lower for the S&P 500 and Nasdaq while crude rose and semiconductors slumped. In the later snapshot, WTI was $91.15 with a โˆ’0.37% change and gold was $4,215.30 with a +1.40% change. The Treasury action targeting Iran's shadow fleet is a separate event; the timing does not prove it moved oil.", "source_urls": [ "https://x.com/ReutersBiz/status/2108354257128743333", "https://x.com/USTreasury/status/2108301161686348240" ] }, { "speaker_id": "marcus", "text": "The Federal Reserve released its 2025 Survey of Consumer Finances, and Michigan's October sentiment and inflation-expectations updates were also listed. The supplied cut has no survey readings or changes, so we cannot say confidence rose or expectations moved. It also reports August consumer credit rose without giving the amount.", "source_urls": [ "https://x.com/federalreserve/status/2108560007457591745", "https://x.com/LizAnnSonders/status/2108560037492707376", "https://x.com/LizAnnSonders/status/2108563278196830240", "https://x.com/KobeissiLetter/status/2108544668745052305" ] }, { "speaker_id": "priya", "text": "Anthropic announced a cyber program for critical-infrastructure defense. That adds an AI security-use case to the day's policy and technology mix, but the announcement does not quantify adoption, spending, or business outcomes. It should stay a context signal rather than an earnings conclusion.", "source_urls": [ "https://x.com/AnthropicAI/status/2108302539498414208" ] } ], "source_urls": [ "https://x.com/AtlantaFed/status/2108239231348855087", "https://x.com/AtlantaFed/status/2108244536119918881", "https://x.com/OECD/status/2108286722488361066", "https://x.com/OECD/status/2108543049479463355", "https://x.com/IMFNews/status/2108125420768157800", "https://x.com/ReutersBiz/status/2108354257128743333", "https://x.com/USTreasury/status/2108301161686348240", "https://x.com/federalreserve/status/2108560007457591745", "https://x.com/LizAnnSonders/status/2108560037492707376", "https://x.com/LizAnnSonders/status/2108563278196830240", "https://x.com/KobeissiLetter/status/2108544668745052305", "https://x.com/AnthropicAI/status/2108302539498414208" ] }, "context_roundtable_sources": [ { "event_id": "mi_evt_5784370a81632bc1a9f50bbc", "headline": "GDPNow Q3 2026 nowcast at 3.6%", "url": "https://x.com/AtlantaFed/status/2108239231348855087", "publisher": "Atlanta Fed", "source_quality": "primary", "public_safe": true, "published_at": "2026-10-08T17:39:00Z", "available_at": "2026-10-08T17:39:00+00:00" }, { "event_id": "mi_evt_2d0cb38a050de6cf9af8045d", "headline": "Wage Growth Tracker eased to 3.9% in September", "url": "https://x.com/AtlantaFed/status/2108244536119918881", "publisher": "Atlanta Fed", "source_quality": "primary", "public_safe": true, "published_at": "2026-10-08T17:39:00Z", "available_at": "2026-10-08T17:39:00+00:00" }, { "event_id": "mi_evt_92ca2bbaacff891d1557a34b", "headline": "Targeted transfers are more cost-effective than broad subsidies", "url": "https://x.com/IMFNews/status/2108125420768157800", "publisher": "International Monetary Fund", "source_quality": "primary", "public_safe": true, "published_at": "2026-10-08T19:39:00Z", "available_at": "2026-10-08T19:39:00+00:00" }, { "event_id": "mi_evt_84c7a89c2e89bd11c9b49d36", "headline": "OECD energy inflation reached 13.6% in August", "url": "https://x.com/OECD/status/2108286722488361066", "publisher": "OECD", "source_quality": "primary", "public_safe": true, "published_at": "2026-10-08T20:39:00Z", "available_at": "2026-10-08T20:39:00+00:00" }, { "event_id": "mi_evt_1ce86fbda767e3cf23e65c7b", "headline": "Anthropic launches cyber program for critical infrastructure defense", "url": "https://x.com/AnthropicAI/status/2108302539498414208", "publisher": "Anthropic", "source_quality": "primary", "public_safe": true, "published_at": "2026-10-08T21:39:00Z", "available_at": "2026-10-08T21:39:00+00:00" }, { "event_id": "mi_evt_73d2a340d7c2289038c1b116", "headline": "Treasury targets remnants of Iran shadow fleet", "url": "https://x.com/USTreasury/status/2108301161686348240", "publisher": "US Department of the Treasury", "source_quality": "primary", "public_safe": true, "published_at": "2026-10-08T21:39:00Z", "available_at": "2026-10-08T21:39:00+00:00" }, { "event_id": "mi_evt_9eb13a013c0d7375bef2c4d7", "headline": "S&P 500 and Nasdaq ended lower as crude rose and semiconductors slumped", "url": "https://x.com/ReutersBiz/status/2108354257128743333", "publisher": "Reuters", "source_quality": "trusted_reporting", "public_safe": true, "published_at": "2026-10-09T00:25:00Z", "available_at": "2026-10-09T00:25:00+00:00" }, { "event_id": "mi_evt_7c7c8da725cea944c9691e8f", "headline": "OECD food inflation eases in August", "url": "https://x.com/OECD/status/2108543049479463355", "publisher": "OECD", "source_quality": "primary", "public_safe": true, "published_at": "2026-10-09T13:00:12.488000Z", "available_at": "2026-10-09T13:00:12.488000+00:00" }, { "event_id": "mi_evt_75b33446e0c53ce864628b34", "headline": "US consumer credit rises in August", "url": "https://x.com/KobeissiLetter/status/2108544668745052305", "publisher": "The Kobeissi Letter", "source_quality": "market_context", "public_safe": true, "published_at": "2026-10-09T13:06:38.551000Z", "available_at": "2026-10-09T13:06:38.551000+00:00" }, { "event_id": "mi_evt_0f9df192ffec3e60cb08975e", "headline": "Federal Reserve releases 2025 Survey of Consumer Finances", "url": "https://x.com/federalreserve/status/2108560007457591745", "publisher": "Federal Reserve", "source_quality": "primary", "public_safe": true, "published_at": "2026-10-09T14:07:35.585000Z", "available_at": "2026-10-09T14:07:35.585000+00:00" }, { "event_id": "mi_evt_21f3c6ab883de9f5d0e91c0c", "headline": "University of Michigan October consumer sentiment", "url": "https://x.com/LizAnnSonders/status/2108560037492707376", "publisher": "Liz Ann Sonders", "source_quality": "market_context", "public_safe": true, "published_at": "2026-10-09T14:07:42.746000Z", "available_at": "2026-10-09T14:07:42.746000+00:00" }, { "event_id": "mi_evt_4a151a4e7588b66b9ab5d68d", "headline": "University of Michigan October inflation expectations", "url": "https://x.com/LizAnnSonders/status/2108563278196830240", "publisher": "Liz Ann Sonders", "source_quality": "market_context", "public_safe": true, "published_at": "2026-10-09T14:20:35.390000Z", "available_at": "2026-10-09T14:20:35.390000+00:00" } ] }, "updates": [ { "day": 16, "timestamp": "2026-11-02T16:16:30.959227Z", "date": "Session 16 ยท Nov 2, 2026 ยท 11:16 NYSE", "text": "The tracked TEVA gain fell 0.98 points to +0.25%; the latest capture was down 1.07% on 0.45ร— average volume and only 0.13% above VWAP. Its 20-session return trails Healthcare by 4.85 points, weakening the relative-strength premise; the prepared record still lacks issuer or FDA confirmation of Weltruza and evidence of access, uptake, or commercial contribution.", "price": 41.64, "pct": 0.25, "return_vs_entry_pct": 0.14, "return_vs_base_pct": 0.14, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -1.09, "session_day": 16, "reference_price": 41.58, "reference_text": "$41.64 ยท +0.14% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "weakens", "claim": "A reported Weltruza approval and positive relative strength can support conditional follow-through, while access and commercial uptake remain unproven.", "summary": "The tracked return and 20-session sector comparison weakened, although the price remained slightly above VWAP. The capture does not resolve the missing issuer or FDA confirmation or the commercial contribution.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-11-02T15:08:10.010071Z", "value": 0.25, "rationale": "Tracked return was +0.25% at the current capture, down 0.98 percentage points since the prior public update." } ] }, "price_as_of": null, "vwap_as_of": null }, { "day": 15, "timestamp": "2026-10-30T21:07:20.278521Z", "date": "Session 15 ยท Oct 30, 2026 ยท 17:07 NYSE", "text": "TEVA tracked return slipped 0.14 percentage points to +1.23% since the previous note, while its 20-session gap to Healthcare narrowed slightly from 5.00 to 4.77 points. That is a small relative improvement, but TEVA still trails its sector, and the sealed evidence still has no issuer or FDA confirmation of Weltruza or evidence of patient access, uptake, or commercial contribution.", "price": 42.09, "pct": 1.23, "return_vs_entry_pct": 1.23, "return_vs_base_pct": 1.23, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.38, "session_day": 15, "reference_price": 41.58, "reference_text": "$42.09 ยท +1.23% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "unassessed", "claim": "The reported Weltruza approval must be confirmed and followed by evidence of patient access or uptake.", "summary": "The current sealed handoff contains no issuer or FDA confirmation and no access, uptake, or commercial-contribution evidence; the small market-relative improvement does not assess this product claim.", "evidence_refs": [] }, "price_as_of": "2026-10-30T20:02:17Z", "vwap_as_of": null }, { "day": 15, "timestamp": "2026-10-30T16:06:31.163341Z", "date": "Session 15 ยท Oct 30, 2026 ยท 12:06 NYSE", "text": "TEVA's tracked return improved 1.63 points to +1.37% as shares rose 1.88% and held 0.13% above VWAP on 0.40 times normal volume. The 20-session gap to Healthcare narrowed to 5.00 points, but the reported Weltruza approval still lacks issuer or FDA confirmation; access, uptake and commercial contribution remain unmeasured.", "price": 42.25, "pct": 1.37, "return_vs_entry_pct": 1.61, "return_vs_base_pct": 1.61, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 1.87, "session_day": 15, "reference_price": 41.58, "reference_text": "$42.25 ยท +1.61% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "unassessed", "claim": "The reported Weltruza approval and its follow-through into access, uptake and revenue.", "summary": "No issuer or FDA confirmation, access, uptake or commercial contribution is available in this handoff; the market capture cannot resolve those company questions.", "evidence_refs": [] }, "price_as_of": "2026-10-30T15:07:39.756955Z", "vwap_as_of": null }, { "day": 15, "timestamp": "2026-10-30T00:23:01.224837Z", "date": "Session 15 ยท Oct 29, 2026 ยท 20:23 NYSE", "text": "TEVAโ€™s tracked return remained slightly negative at 0.26%, while the latest capture held above its average trading price near the session high on 0.93 times normal volume. That firm day has not repaired the 5.78-point 20-session lag to Healthcare or confirmed Weltruzaโ€™s approval, access or uptake, so the follow-through claim remains unproven.", "price": 41.47, "pct": -0.26, "return_vs_entry_pct": -0.26, "return_vs_base_pct": -0.26, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.0, "session_day": 15, "reference_price": 41.58, "reference_text": "$41.47 ยท -0.26% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "weakens", "claim": "The reported Weltruza approval, together with positive relative performance and a constructive tape, supports a testable follow-through thesis.", "summary": "The latest positive session held, but the tracked return remains -0.26% and the 20-session Healthcare gap widened to 5.78 points. Weltruza confirmation, access and uptake remain unverified.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-29T23:29:15.746078Z", "value": -0.26, "rationale": "The tracked return remains slightly negative and the 20-session Healthcare relative gap widened; the thesis condition is not yet met." }, { "kind": "market_observation", "field": "volume_ratio", "as_of": "2026-10-29T23:29:15.746078Z", "value": 0.93, "rationale": "Near-normal participation supported the session rebound, but does not establish lasting relative strength or Weltruza uptake." } ] }, "price_as_of": "2026-10-29T23:14:19Z", "vwap_as_of": null }, { "day": 14, "timestamp": "2026-10-29T20:54:24.669958Z", "date": "Session 14 ยท Oct 29, 2026 ยท 16:54 NYSE", "text": "TEVA's tracked loss narrowed 1.53 points to 0.26% by session 14 as shares rose 3.75%, finished above VWAP and near the day's high, though volume stayed below its recent norm. It still trails Healthcare by 5.24 points over 20 sessions, and the near-flat one-session model does little to settle the rebound. Weltruza's reported approval still lacks issuer or FDA confirmation; access and uptake remain unverified.", "price": 41.47, "pct": -0.26, "return_vs_entry_pct": -0.26, "return_vs_base_pct": -0.26, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 1.65, "session_day": 14, "reference_price": 41.58, "reference_text": "$41.47 ยท -0.26% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": true, "active_relevant": true, "terminal_closure": false, "transcript_anchor": "transcript-entry-8d8355eb927ae758db52ff5216ec1068dde65324d6f5dc3d11f2cb78b9e6be65", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "weakens", "claim": "The reported Weltruza approval, relative strength and constructive tape support a conditional 15-session follow-through thesis.", "summary": "The strong session-14 rebound improves the tape, but TEVA remains slightly below its entry reference and still trails Healthcare over 20 sessions. The supplied record does not establish confirmation, access or uptake for Weltruza.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-29T20:23:19.274844Z", "value": -0.26, "rationale": "The tracked return remains slightly negative at session 14 despite the latest rebound, which weakens the original follow-through claim." }, { "kind": "market_observation", "field": "volume_ratio", "as_of": "2026-10-29T20:23:19.274844Z", "value": 0.93, "rationale": "The session gain arrived on below-usual volume, limiting its confirmation of sustained participation." } ] }, "price_as_of": "2026-10-29T20:01:12Z", "vwap_as_of": null }, { "day": 14, "timestamp": "2026-10-29T16:11:13.859456Z", "date": "Session 14 ยท Oct 29, 2026 ยท 12:11 NYSE", "text": "TEVA's tracked loss narrowed 2.08 points to 1.79% as shares rose 2.04% and reclaimed VWAP; the 20-session Healthcare gap remains 6.55 points against it. This repairs the prior below-VWAP reading but leaves relative performance weak. The reported Weltruza approval still lacks issuer or FDA confirmation, while launch access and uptake remain unverified.", "price": 40.785, "pct": -1.79, "return_vs_entry_pct": -1.91, "return_vs_base_pct": -1.91, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 1.96, "session_day": 14, "reference_price": 41.58, "reference_text": "$40.78 ยท -1.91% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "unchanged", "claim": "The reported Weltruza approval may support the thesis if it is confirmed and patient access and uptake follow.", "summary": "The price recovered above VWAP and reduced the tracked loss, but relative performance still trails Healthcare and the reported approval remains unconfirmed.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-29T15:07:08.876936Z", "value": -1.79, "rationale": "The tracked loss improved 2.08 points from the previous note." }, { "kind": "market_observation", "field": "vwap", "as_of": "2026-10-29T15:07:08.876936Z", "value": 40.72, "rationale": "The current 40.785 capture is 0.16% above VWAP." }, { "kind": "market_observation", "field": "price", "as_of": "2026-10-29T15:07:08.876936Z", "value": 40.785, "rationale": "The 20-session Healthcare lag remains 6.55 points." } ] }, "price_as_of": "2026-10-29T15:07:08.876936Z", "vwap_as_of": null }, { "day": 13, "timestamp": "2026-10-28T22:47:40.783927Z", "date": "Session 13 ยท Oct 28, 2026 ยท 18:47 NYSE", "text": "TEVAโ€™s tracked loss stayed at 3.87% as shares fell 1.04% in the latest regular-session capture, closed below VWAP and traded at 0.81 times usual volume. It still trails Healthcare by 5.78 points over 20 sessions, while launch access and uptake for Weltruza remain unverified.", "price": 39.97, "pct": -3.87, "return_vs_entry_pct": -3.87, "return_vs_base_pct": -3.87, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.0, "session_day": 13, "reference_price": 41.58, "reference_text": "$39.97 ยท -3.87% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "weakens", "claim": "The reported FDA approval of Weltruza, together with TEVAโ€™s positive relative performance and constructive captured tape, supports a testable follow-through thesis over the next 15 trading sessions.", "summary": "TEVA remains below its original reference and trails Healthcare over 20 sessions. The relative-strength condition has not recovered, while launch access and uptake remain unverified.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-28T22:26:22.807505Z", "value": -3.87, "rationale": "The tracked return remains negative, so the published positive-performance condition is not currently met." }, { "kind": "market_observation", "field": "volume_ratio", "as_of": "2026-10-28T22:26:22.807505Z", "value": 0.81, "rationale": "Below-average session volume offers limited confirmation of a renewed follow-through move." } ] }, "price_as_of": "2026-10-28T21:45:07Z", "vwap_as_of": null }, { "day": 13, "timestamp": "2026-10-28T21:48:31.104553Z", "date": "Session 13 ยท Oct 28, 2026 ยท 17:48 NYSE", "text": "TEVA's tracked loss widened 1.20 points to 3.87%; the latest capture was 0.35% below VWAP on 0.81 times usual volume. Its 20-session return trails Healthcare by 5.78 points, and the packet adds no evidence about Weltruza launch access or uptake; the modest tape repair in the prior note has not held.", "price": 39.97, "pct": -3.87, "return_vs_entry_pct": -3.87, "return_vs_base_pct": -3.87, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.86, "session_day": 13, "reference_price": 41.58, "reference_text": "$39.97 ยท -3.87% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "weakens", "claim": "The market follow-through weakened while launch access and uptake remain unverified.", "summary": "The tracked loss widened, the latest capture fell below VWAP and TEVA trails Healthcare over 20 sessions. The supplied evidence does not establish Weltruza launch access or uptake, so the market and commercial follow-through remain weak.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-28T20:26:19.375087Z", "value": -3.87, "rationale": "The tracked loss widened to 3.87% and the latest capture is below VWAP; the 20-session comparison trails Healthcare by 5.78 points." } ] }, "price_as_of": "2026-10-28T20:01:41Z", "vwap_as_of": null }, { "day": 13, "timestamp": "2026-10-28T15:53:52.695070Z", "date": "Session 13 ยท Oct 28, 2026 ยท 11:53 NYSE", "text": "The tracked loss eased 0.19 points to 2.67%; shares were slightly lower but remained above VWAP on light volume. This modest tape repair does not confirm Weltruza approval, launch access or uptake.", "price": 40.33, "pct": -2.67, "return_vs_entry_pct": -3.01, "return_vs_base_pct": -3.01, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.15, "session_day": 13, "reference_price": 41.58, "reference_text": "$40.33 ยท -3.01% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "strengthens", "claim": "Reported Weltruza approval and positive relative performance support a testable follow-through thesis.", "summary": "The tracked loss narrowed slightly and price held above VWAP, modestly supporting the market leg; approval, access and uptake remain unconfirmed in this handoff.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-28T15:06:48.246244Z", "value": -2.67, "rationale": "The current tracked return is -2.67%; change since the prior public update is 0.19 percentage points." }, { "kind": "market_observation", "field": "price", "as_of": "2026-10-28T15:06:48.246244Z", "value": 40.33, "rationale": "The current price is 40.33, with VWAP at 40.11 and captured price state above." } ] }, "price_as_of": "2026-10-28T15:06:48.246244Z", "vwap_as_of": null }, { "day": 13, "timestamp": "2026-10-28T01:22:39.387544Z", "date": "Session 13 ยท Oct 27, 2026 ยท 21:22 NYSE", "text": "TEVA's day-13 tracked loss stayed at 2.86% as shares rose 1.10% on near-normal volume and finished 0.35% above VWAP. The current 20-session comparison shows a 1.93-point lag to Healthcare, narrower than the 3.49-point gap in the previous note. That tape repair is modest; this packet still adds no confirmation of Weltruza's reported approval, launch access or uptake.", "price": 40.39, "pct": -2.86, "return_vs_entry_pct": -2.86, "return_vs_base_pct": -2.86, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.0, "session_day": 13, "reference_price": 41.58, "reference_text": "$40.39 ยท -2.86% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "weakens", "claim": "Reported Weltruza FDA approval plus positive relative performance may support a 15-session follow-through test; launch access, uptake and revenue are not established.", "summary": "The tracked loss remains 2.86%; the Healthcare lag narrowed to 1.93 points, while evidence confirming Weltruza approval, launch access or uptake remains absent.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-27T22:42:15.523138Z", "value": -2.86, "rationale": "The tracked loss and continued Healthcare underperformance test the thesis conditions of positive relative performance and commercial follow-through." } ] }, "price_as_of": "2026-10-27T22:44:55Z", "vwap_as_of": null }, { "day": 12, "timestamp": "2026-10-27T22:42:27.192692Z", "date": "Session 12 ยท Oct 27, 2026 ยท 18:42 NYSE", "text": "The tracked loss widened 0.17 points to 2.86%, even as shares rose 1.10% and finished 0.35% above the session average price on near-normal volume. The 20-session return still trails Healthcare by 3.49 points. The prepared packet adds no evidence on the reported Weltruza approval, launch access or uptake, so the modest tape repair does not validate the commercial case.", "price": 40.39, "pct": -2.86, "return_vs_entry_pct": -2.86, "return_vs_base_pct": -2.86, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.27, "session_day": 12, "reference_price": 41.58, "reference_text": "$40.39 ยท -2.86% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "unassessed", "claim": "Weltruza approval can translate into launch access and patient uptake.", "summary": "The current packet contains no new evidence on approval, access or uptake; the modest market move cannot assess the commercial claim.", "evidence_refs": [] }, "price_as_of": "2026-10-27T21:07:40Z", "vwap_as_of": null }, { "day": 12, "timestamp": "2026-10-27T16:12:29.770550Z", "date": "Session 12 ยท Oct 27, 2026 ยท 12:12 NYSE", "text": "Teva tracking loss narrowed 1.23 points to 2.69% as shares rose 1.39% just above VWAP. The twenty-session return still trails Healthcare by 3.19 points and volume was 0.38 times average. This modest tape repair does not verify the reported Weltruza approval or any launch access and uptake.", "price": 40.505, "pct": -2.69, "return_vs_entry_pct": -2.59, "return_vs_base_pct": -2.59, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 1.33, "session_day": 12, "reference_price": 41.58, "reference_text": "$40.51 ยท -2.59% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "unassessed", "claim": "Issuer or regulator confirmation of the reported Weltruza approval and evidence of access and uptake support the operating path.", "summary": "The 1.23-point price repair is modest and the twenty-session Healthcare-relative gap remains negative; the packet does not add primary approval or launch evidence.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-27T15:08:16.729992Z", "value": -2.69, "rationale": "The current tracked return improved from the last public note, but it does not establish the reported product approval or its commercial effect." }, { "kind": "market_observation", "field": "vwap", "as_of": "2026-10-27T15:08:16.729992Z", "value": 40.46, "rationale": "Price was only 0.11% above the current session VWAP, a limited intraday confirmation." } ] }, "price_as_of": "2026-10-27T15:08:16.729992Z", "vwap_as_of": null }, { "day": 12, "timestamp": "2026-10-27T11:07:44Z", "date": "Session 12 ยท Oct 27, 2026 ยท 07:07 NYSE", "text": "Teva rose 1.37% at the latest regular close to $39.95, but remains down 3.92% from entry and trails Healthcare by 1.93 points over 20 sessions.", "price": 39.95, "pct": -3.92, "return_vs_entry_pct": -3.92, "return_vs_base_pct": -3.92, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.0, "session_day": 12, "reference_price": 41.58, "reference_text": "$39.95 ยท -3.92% from $41.58 base", "timing": "", "market_marker": { "phase": "post", "text": "Aftermarket update: $39.95 (0.00% vs regular close) ยท Oct 26, 2026 ยท 18:12 NYSE" }, "extended_hours": { "phase": "post", "price": 39.95, "ext_pct": 0.0, "as_of": "2026-10-26T22:12:21Z", "persisted": true }, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": { "schema_version": "tryding-thesis-change.v1", "assessment": "weakens", "claim": "Weltruza's reported approval and positive relative performance support follow-through, while access and uptake remain unproven.", "summary": "The episode remains below entry and now trails Healthcare over 20 sessions, weakening the market follow-through leg. The cut adds no evidence on launch access, uptake, or revenue contribution.", "evidence_refs": [ { "kind": "market_observation", "field": "return_vs_entry_pct", "as_of": "2026-10-27T10:40:51.050790Z", "value": -3.92, "rationale": "The tracking return remains negative despite the latest regular-session gain." } ] }, "price_as_of": "2026-10-26T22:12:21Z", "vwap_as_of": null }, { "day": 11, "timestamp": "2026-10-26T23:42:15.411059Z", "date": "Session 11 ยท Oct 26, 2026 ยท 19:42 NYSE", "text": "Teva's tracking loss narrowed by 0.38 percentage point to 3.92% in session 11 as shares rose 1.37% to $39.95 and held above VWAP. The improvement is modest, and the record still contains no evidence that Weltruza has secured access, gained uptake, or contributed meaningfully to sales.", "price": 39.95, "pct": -3.92, "return_vs_entry_pct": -3.92, "return_vs_base_pct": -3.92, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.0, "session_day": 11, "reference_price": 41.58, "reference_text": "$39.95 ยท -3.92% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-26T21:46:32Z", "vwap_as_of": null }, { "day": 11, "timestamp": "2026-10-26T21:56:02.430405Z", "date": "Session 11 ยท Oct 26, 2026 ยท 17:56 NYSE", "text": "The tracked loss for TEVA narrowed 0.38 points to 3.92% on session 11 as shares gained 1.37% to $39.95 and stayed 0.63% above VWAP. TEVA still trails Healthcare by 1.93 points over 20 sessions, and no new evidence establishes access, uptake or commercial contribution for Weltruza. The price repair is visible; the product thesis still lacks a verified commercial bridge.", "price": 39.95, "pct": -3.92, "return_vs_entry_pct": -3.92, "return_vs_base_pct": -3.92, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.26, "session_day": 11, "reference_price": 41.58, "reference_text": "$39.95 ยท -3.92% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-26T20:00:35Z", "vwap_as_of": null }, { "day": 11, "timestamp": "2026-10-26T16:20:15.737520Z", "date": "Session 11 ยท Oct 26, 2026 ยท 12:20 NYSE", "text": "On session 11, TEVAโ€™s tracked loss narrowed 0.92 points to 4.30%; shares rose 1.09%, held 0.50% above VWAP near the high on a normal 0.99 time-adjusted pace. TEVA still trails Healthcare by 2.28 points over 20 sessions, and the packet adds no evidence of Weltruza access, uptake or commercial contribution.", "price": 39.84, "pct": -4.3, "return_vs_entry_pct": -4.18, "return_vs_base_pct": -4.18, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 1.04, "session_day": 11, "reference_price": 41.58, "reference_text": "$39.84 ยท -4.18% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-26T15:19:48.386219Z", "vwap_as_of": null }, { "day": 10, "timestamp": "2026-10-23T22:02:58.695052Z", "date": "Session 10 ยท Oct 23, 2026 ยท 18:02 NYSE", "text": "The tracked loss narrowed 0.10 points to 5.22% on session 10, though the latest capture still showed a 1.99% decline to $39.41 below VWAP. TEVA remains 4.47 points behind Healthcare over 20 sessions; the reported Weltruza approval keeps the catalyst testable, but the package still shows no launch access, uptake or commercial contribution.", "price": 39.41, "pct": -5.22, "return_vs_entry_pct": -5.22, "return_vs_base_pct": -5.22, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.1, "session_day": 10, "reference_price": 41.58, "reference_text": "$39.41 ยท -5.22% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-23T21:21:49Z", "vwap_as_of": null }, { "day": 10, "timestamp": "2026-10-23T20:15:24.510922Z", "date": "Session 10 ยท Oct 23, 2026 ยท 16:15 NYSE", "text": "The tracked loss widened 0.37 points to 5.32% on session 10. Shares fell 2.09% to $39.37 below VWAP on 0.71 times usual volume; the 20-session Healthcare lag is 4.41 points. The market test weakened after Weltruza approval, while this handoff provides no new evidence of launch uptake or commercial contribution.", "price": 39.37, "pct": -5.32, "return_vs_entry_pct": -5.32, "return_vs_base_pct": -5.32, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -1.02, "session_day": 10, "reference_price": 41.58, "reference_text": "$39.37 ยท -5.32% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-23T19:22:12.987963Z", "vwap_as_of": null }, { "day": 10, "timestamp": "2026-10-23T14:56:34.161537Z", "date": "Session 10 ยท Oct 23, 2026 ยท 10:56 NYSE", "text": "The tracked loss widened 1.66 points to 4.95% on session 10 as shares fell 1.04% to $39.79, though they stayed 0.84% above the session average on 1.96 times usual time-adjusted activity. The 20-session Healthcare lag narrowed to 3.88 points, but the evidence still does not show Weltruza approval turning into access, uptake or revenue.", "price": 39.79, "pct": -4.95, "return_vs_entry_pct": -4.3, "return_vs_base_pct": -4.3, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -1.01, "session_day": 10, "reference_price": 41.58, "reference_text": "$39.79 ยท -4.30% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-23T14:06:04.621810Z", "vwap_as_of": null }, { "day": 9, "timestamp": "2026-10-22T22:04:32.563215Z", "date": "Session 9 ยท Oct 22, 2026 ยท 18:04 NYSE", "text": "The tracked loss narrowed 0.34 points to 3.29% on session 9, despite shares falling 1.01% to $40.21 on 0.71 times average volume. The 20-session return still trails Healthcare by 6.75 points, and the separate duvakitug study update does not establish Weltruza access or uptake; the central commercial question remains open.", "price": 40.21, "pct": -3.29, "return_vs_entry_pct": -3.29, "return_vs_base_pct": -3.29, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.35, "session_day": 9, "reference_price": 41.58, "reference_text": "$40.21 ยท -3.29% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-22T20:00:36Z", "vwap_as_of": null }, { "day": 9, "timestamp": "2026-10-22T19:38:49.428606Z", "date": "Session 9 ยท Oct 22, 2026 ยท 15:38 NYSE", "text": "TEVA's tracked loss widened 1.32 points to 3.63% on session 9; shares fell 1.37% to $40.07 but held slightly above the session's average price near midrange on 0.54 times usual volume. Its 20-session return now trails Healthcare by 7.20 points, versus 1.88 points in the last note. Teva's separate phase 2b update for investigational duvakitug adds pipeline evidence, but does not confirm Weltruza access or uptake; the active model remains close to even.", "price": 40.065, "pct": -3.63, "return_vs_entry_pct": -3.64, "return_vs_base_pct": -3.64, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -1.33, "session_day": 9, "reference_price": 41.58, "reference_text": "$40.06 ยท -3.64% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": true, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "transcript-entry-06560766ff5409c69cc6e0faf40df96e3acec9254701bb49c87ea8d16d00b112", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-22T19:21:50.306215Z", "vwap_as_of": null }, { "day": 8, "timestamp": "2026-10-21T21:52:31.040445Z", "date": "Session 8 ยท Oct 21, 2026 ยท 17:52 NYSE", "text": "TEVA widened its tracked loss by 0.55 points to -2.31% on session 8. The latest quote was $40.62, down 0.56%; the available regular-session read sat just below VWAP as activity eased. TEVA now trails Healthcare by 1.88 points over twenty sessions. Without primary confirmation of Weltruza approval, launch access or uptake, the price drift adds little thesis support.", "price": 40.62, "pct": -2.31, "return_vs_entry_pct": -2.31, "return_vs_base_pct": -2.31, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.55, "session_day": 8, "reference_price": 41.58, "reference_text": "$40.62 ยท -2.31% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-21T20:32:10Z", "vwap_as_of": null }, { "day": 8, "timestamp": "2026-10-21T00:36:13.260801Z", "date": "Session 8 ยท Oct 20, 2026 ยท 20:36 NYSE", "text": "TEVA's tracked loss held at 1.76% on session 8 as shares fell 1.11% to $40.85, 0.28% below VWAP, with 0.43 time-adjusted activity. The stock now trails Healthcare by 0.81 points over 20 sessions; without primary confirmation of Weltruza's reported approval or evidence of launch access and uptake, this drift gives the thesis little new support.", "price": 40.85, "pct": -1.76, "return_vs_entry_pct": -1.76, "return_vs_base_pct": -1.76, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.7, "session_day": 8, "reference_price": 41.58, "reference_text": "$40.85 ยท -1.76% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-20T23:20:55Z", "vwap_as_of": null }, { "day": 7, "timestamp": "2026-10-20T23:09:43.955973Z", "date": "Session 7 ยท Oct 20, 2026 ยท 19:09 NYSE", "text": "TEVA tracked loss widened 1.11 points to 1.76% as shares fell 0.41% to $41.14, 0.28% below VWAP on 0.47 times average volume. Its 20-session return now trails Healthcare by 2.17 points; the price drift offers little confirmation, while the handoff still lacks primary confirmation of Weltruza approval or evidence of launch access and uptake.", "price": 41.14, "pct": -1.76, "return_vs_entry_pct": -1.06, "return_vs_base_pct": -1.06, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.41, "session_day": 7, "reference_price": 41.58, "reference_text": "$41.14 ยท -1.06% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-20T19:32:17.054310Z", "vwap_as_of": null }, { "day": 6, "timestamp": "2026-10-19T22:19:40.813674Z", "date": "Session 6 ยท Oct 19, 2026 ยท 18:19 NYSE", "text": "TEVA's tracked loss widened 0.43 percentage points to 0.65% as shares fell 0.46%, ending just 0.01% above VWAP on 0.66 times average volume. Its 20-session return now trails Healthcare by 0.81 points; this price update adds no evidence on the reported Weltruza approval, whose primary confirmation and commercial uptake remain open.", "price": 41.31, "pct": -0.65, "return_vs_entry_pct": -0.65, "return_vs_base_pct": -0.65, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.4, "session_day": 6, "reference_price": 41.58, "reference_text": "$41.31 ยท -0.65% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-19T21:28:10Z", "vwap_as_of": null }, { "day": 6, "timestamp": "2026-10-19T20:01:44.897519Z", "date": "Session 6 ยท Oct 19, 2026 ยท 16:01 NYSE", "text": "TEVA's tracked loss edged 0.03 points wider to 0.22% as the quote slipped 0.06%, held just 0.01% above VWAP and traded at 0.32 times normal volume. Its 20-session return trails Healthcare by 0.63 points; the reported Weltruza approval still lacks primary confirmation here, and launch access, uptake and revenue contribution remain open questions.", "price": 41.475, "pct": -0.22, "return_vs_entry_pct": -0.25, "return_vs_base_pct": -0.25, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.06, "session_day": 6, "reference_price": 41.58, "reference_text": "$41.48 ยท -0.25% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-19T19:21:30.182691Z", "vwap_as_of": null }, { "day": 5, "timestamp": "2026-10-16T22:05:51.393860Z", "date": "Session 5 ยท Oct 16, 2026 ยท 18:05 NYSE", "text": "TEVA's tracked loss narrowed 0.27 points to 0.19% as the latest quote rose 0.95%, held 0.24% above VWAP and traded near mid-range on normal volume. Its Healthcare lead is 1.52 points over 20 sessions, but Weltruza's approval still lacks primary confirmation and launch access, uptake and revenue remain unestablished; price support improves without resolving the catalyst.", "price": 41.5, "pct": -0.19, "return_vs_entry_pct": -0.19, "return_vs_base_pct": -0.19, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.32, "session_day": 5, "reference_price": 41.58, "reference_text": "$41.50 ยท -0.19% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-16T21:23:15Z", "vwap_as_of": null }, { "day": 5, "timestamp": "2026-10-16T20:10:58.230312Z", "date": "Session 5 ยท Oct 16, 2026 ยท 16:10 NYSE", "text": "The tracked loss for TEVA widened 0.45 points to 0.46% despite a 0.63% latest-session rise above the volume-weighted average on 0.76x normal volume. It retains only a 1.32-point 20-session lead over Healthcare; the reported Weltruza approval lacks primary confirmation, while access, uptake and revenue remain unestablished.", "price": 41.37, "pct": -0.46, "return_vs_entry_pct": -0.51, "return_vs_base_pct": -0.51, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.53, "session_day": 5, "reference_price": 41.58, "reference_text": "$41.37 ยท -0.51% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-16T19:21:22.647785Z", "vwap_as_of": null }, { "day": 5, "timestamp": "2026-10-16T14:22:44.863836Z", "date": "Session 5 ยท Oct 16, 2026 ยท 10:22 NYSE", "text": "TEVA's tracked return improved 1.12 points to a 0.01% loss as the quote rose 1.17% and held 0.14% above VWAP, though volume was only 0.07 of normal. A 1.01-point 20-session lead over Healthcare is modest, and the reported Weltruza approval still lacks primary confirmation; access, uptake and revenue remain unestablished.", "price": 41.5902, "pct": -0.01, "return_vs_entry_pct": 0.02, "return_vs_base_pct": 0.02, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 1.15, "session_day": 5, "reference_price": 41.58, "reference_text": "$41.59 ยท +0.02% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-16T14:06:07.820265Z", "vwap_as_of": null }, { "day": 4, "timestamp": "2026-10-15T22:12:05.949106Z", "date": "Session 4 ยท Oct 15, 2026 ยท 18:12 NYSE", "text": "TEVA's tracked return fell 0.72 percentage points to a 1.13% loss even as the latest quote rose 0.96% on 1.59 times average volume; post-market trading was 0.34% lower. That makes the tape mixed rather than a confirmed recovery. The Weltruza approval report still lacks primary confirmation in the packet, and launch access, uptake and revenue are not established.", "price": 41.11, "pct": -1.13, "return_vs_entry_pct": -1.13, "return_vs_base_pct": -1.13, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.58, "session_day": 4, "reference_price": 41.58, "reference_text": "$41.11 ยท -1.13% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-15T21:01:56Z", "vwap_as_of": null }, { "day": 4, "timestamp": "2026-10-15T20:17:44.982139Z", "date": "Session 4 ยท Oct 15, 2026 ยท 16:17 NYSE", "text": "TEVA's tracked return fell 0.70 points to a 0.41% loss even as shares rose 1.55% in the latest capture; price remained just below VWAP and its 20-session lead over Healthcare is effectively flat at 0.10 points. The Weltruza approval thesis has not yet gained market or operating confirmation on launch access, uptake or revenue.", "price": 41.35, "pct": -0.41, "return_vs_entry_pct": -0.55, "return_vs_base_pct": -0.55, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.92, "session_day": 4, "reference_price": 41.58, "reference_text": "$41.35 ยท -0.55% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-15T19:21:33.629030Z", "vwap_as_of": null }, { "day": 4, "timestamp": "2026-10-15T15:34:44.342940Z", "date": "Session 4 ยท Oct 15, 2026 ยท 11:34 NYSE", "text": "TEVA's tracked return recovered 2.36 points to a 0.29% gain; shares rose 2.49% and held 0.50% above VWAP near the top of the range. The 20-session lead over Healthcare narrowed to 1.00 point, so the price repair is constructive but the Weltruza approval still has no established access, uptake or revenue contribution.", "price": 41.735, "pct": 0.29, "return_vs_entry_pct": 0.37, "return_vs_base_pct": 0.37, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 2.44, "session_day": 4, "reference_price": 41.58, "reference_text": "$41.73 ยท +0.37% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-15T14:06:44.673876Z", "vwap_as_of": null }, { "day": 3, "timestamp": "2026-10-14T21:46:07.581524Z", "date": "Session 3 ยท Oct 14, 2026 ยท 17:46 NYSE", "text": "TEVA tracked loss widened 0.84 points to 2.07%; shares fell 1.28% in the regular session, ended 1.90% below VWAP near the session low, and were flat after hours. The 20-session lead over Healthcare remains 1.99 points, but the weak close adds pressure to the follow-through case. The reported Weltruza approval still does not establish access, uptake, or revenue contribution.", "price": 40.72, "pct": -2.07, "return_vs_entry_pct": -2.07, "return_vs_base_pct": -2.07, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.92, "session_day": 3, "reference_price": 41.58, "reference_text": "$40.72 ยท -2.07% from $41.58 base", "timing": "", "market_marker": { "phase": "post", "text": "Aftermarket update: $40.72 (0.00% vs regular close) ยท Oct 14, 2026 ยท 17:19 NYSE" }, "extended_hours": { "phase": "post", "price": 40.72, "ext_pct": 0.0, "as_of": "2026-10-14T21:19:19Z", "persisted": false }, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-14T21:19:19Z", "vwap_as_of": null }, { "day": 3, "timestamp": "2026-10-14T20:37:22.925832Z", "date": "Session 3 ยท Oct 14, 2026 ยท 16:37 NYSE", "text": "Teva's tracked return fell 1.57 points into a 1.23% loss as shares slipped 0.36% and sat about 1% below VWAP near the day's low. Its 20-session lead over Healthcare remains 3.26 points, but the reversal erases the prior return recovery and still does not confirm the reported Weltruza approval or access and uptake.", "price": 41.1, "pct": -1.23, "return_vs_entry_pct": -1.15, "return_vs_base_pct": -1.15, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -1.53, "session_day": 3, "reference_price": 41.58, "reference_text": "$41.10 ยท -1.15% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-14T19:41:13.876792Z", "vwap_as_of": null }, { "day": 3, "timestamp": "2026-10-14T15:09:58.242142Z", "date": "Session 3 ยท Oct 14, 2026 ยท 11:09 NYSE", "text": "TEVA recovered 1.13 points to a tracked gain of 0.34%; shares rose 1.19%, held above VWAP and reached the observed session high. The 20-session lead over Healthcare stands at 5.46 points. The stronger tape does not confirm the reported Weltruza approval, and access or uptake remains unestablished.", "price": 41.74, "pct": 0.34, "return_vs_entry_pct": 0.38, "return_vs_base_pct": 0.38, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 1.17, "session_day": 3, "reference_price": 41.58, "reference_text": "$41.74 ยท +0.38% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-14T14:06:37.850462Z", "vwap_as_of": null }, { "day": 2, "timestamp": "2026-10-13T21:51:19.807333Z", "date": "Session 2 ยท Oct 13, 2026 ยท 17:51 NYSE", "text": "TEVA's tracked loss narrowed 0.26 percentage points to 0.79% as shares rose 0.19% near VWAP but remained in the lower quarter of the range on dollar turnover 1.16 times average. Its 20-session lead over Healthcare is 3.91 points, while the reported Weltruza approval still lacks issuer or FDA confirmation and access and uptake remain unestablished.", "price": 41.25, "pct": -0.79, "return_vs_entry_pct": -0.79, "return_vs_base_pct": -0.79, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.32, "session_day": 2, "reference_price": 41.58, "reference_text": "$41.25 ยท -0.79% from $41.58 base", "timing": "", "market_marker": { "phase": "post", "text": "Aftermarket update: $41.25 (0.00% vs regular close) ยท Oct 13, 2026 ยท 17:28 NYSE" }, "extended_hours": { "phase": "post", "price": 41.25, "ext_pct": 0.0, "as_of": "2026-10-13T21:28:12Z", "persisted": false }, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-13T21:28:12Z", "vwap_as_of": null }, { "day": 2, "timestamp": "2026-10-13T20:08:19.837748Z", "date": "Session 2 ยท Oct 13, 2026 ยท 16:08 NYSE", "text": "Tevaโ€™s tracked loss widened 0.26 points to 1.05%; shares slipped 0.12% below VWAP near the lower range on 0.84 times average volume. The 3.55-point 20-session Healthcare lead offers little help with the key gap: Weltruzaโ€™s reported approval still lacks issuer or FDA confirmation, and access and uptake are unestablished.", "price": 41.12, "pct": -1.05, "return_vs_entry_pct": -1.11, "return_vs_base_pct": -1.11, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -0.67, "session_day": 2, "reference_price": 41.58, "reference_text": "$41.12 ยท -1.11% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-13T19:24:51.998952Z", "vwap_as_of": null }, { "day": 2, "timestamp": "2026-10-13T15:29:18.488139Z", "date": "Session 2 ยท Oct 13, 2026 ยท 11:29 NYSE", "text": "TEVA's tracked loss narrowed 0.20 percentage points to 0.79% as shares rose 0.55% and held 0.23% above the day's volume-weighted average price near the upper range. Its 20-session lead over Healthcare is 4.14 points. The tape is firmer, but the reported Weltruza approval still lacks issuer or FDA confirmation, and the evidence does not establish access, uptake or revenue.", "price": 41.395, "pct": -0.79, "return_vs_entry_pct": -0.44, "return_vs_base_pct": -0.44, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.55, "session_day": 2, "reference_price": 41.58, "reference_text": "$41.40 ยท -0.44% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-13T14:06:26.349567Z", "vwap_as_of": null }, { "day": 1, "timestamp": "2026-10-12T22:08:24.990901Z", "date": "Session 1 ยท Oct 12, 2026 ยท 18:08 NYSE", "text": "TEVA's tracked loss narrowed 0.93 points to 0.99% as shares edged up 0.17% on 1.32 times average volume, yet closed 0.66% below the volume-weighted average price in the lower part of the range. Its 3.80-point 20-session lead over Healthcare persists, but the packet still lacks issuer or FDA confirmation of the reported approval and evidence of access or uptake; the commercial case remains untested.", "price": 41.17, "pct": -0.99, "return_vs_entry_pct": -0.99, "return_vs_base_pct": -0.99, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.75, "session_day": 1, "reference_price": 41.58, "reference_text": "$41.17 ยท -0.99% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-12T21:30:11Z", "vwap_as_of": null }, { "day": 1, "timestamp": "2026-10-12T20:16:46.034117Z", "date": "Session 1 ยท Oct 12, 2026 ยท 16:16 NYSE", "text": "TEVA's first tracked session is down 1.78%; the regular-session capture shows shares down 0.60%, 0.48% below VWAP on 0.78 times average volume. The price response does not confirm the reported approval, which remains secondary in this packet; issuer or FDA confirmation, commercial availability and uptake are still unestablished.", "price": 40.855, "pct": -1.92, "return_vs_entry_pct": -1.74, "return_vs_base_pct": -1.74, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": 0.21, "session_day": 1, "reference_price": 41.58, "reference_text": "$40.85 ยท -1.74% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-12T18:48:37.209746Z", "vwap_as_of": null }, { "day": 1, "timestamp": "2026-10-12T19:47:06.820670Z", "date": "Session 1 ยท Oct 12, 2026 ยท 15:47 NYSE", "text": "TEVA's tracked return is 1.92% below its initial reference on session one; shares are down 0.80% today, 0.66% below their volume-weighted average price and in the lower fifth of the session range on 0.83 times average volume. It still leads Healthcare by 3.03 points over 20 sessions, but the packet does not establish U.S. access, uptake or revenue from the reported Weltruza approval, leaving the commercial path unresolved.", "price": 40.77, "pct": -1.92, "return_vs_entry_pct": -1.95, "return_vs_base_pct": -1.95, "return_vs_prior_pct": null, "previous_regular_close": null, "change_vs_prior_session_pct": -1.95, "session_day": 1, "reference_price": 41.58, "reference_text": "$40.77 ยท -1.95% from $41.58 base", "timing": "", "market_marker": null, "extended_hours": null, "relevant": false, "active_relevant": false, "terminal_closure": false, "transcript_anchor": "", "related_links": [], "thesis_change": null, "price_as_of": "2026-10-12T19:23:05.083706Z", "vwap_as_of": null } ], "observed_outcomes": [ { "label": "+1 sessions", "status": "complete", "return": -0.99, "reference_text": "-0.99% from $41.58 base", "price": 41.17, "price_basis": null, "observation_date": null, "updated": "Oct 12, 2026 ยท 17:38 NYSE", "mfe": -0.22, "mae": -2.36 }, { "label": "+5 sessions", "status": "complete", "return": -0.19, "reference_text": "-0.19% from $41.58 base", "price": 41.5, "price_basis": null, "observation_date": null, "updated": "Oct 16, 2026 ยท 17:05 NYSE", "mfe": 0.7, "mae": -2.36 }, { "label": "+10 sessions", "status": "complete", "return": -5.22, "reference_text": "-5.22% from $41.58 base", "price": 39.41, "price_basis": null, "observation_date": null, "updated": "Oct 23, 2026 ยท 17:05 NYSE", "mfe": 0.72, "mae": -5.95 }, { "label": "+15 sessions", "status": "complete", "return": 1.23, "reference_text": "+1.23% from $41.58 base", "price": 42.09, "price_basis": null, "observation_date": null, "updated": "Oct 30, 2026 ยท 18:06 NYSE", "mfe": 2.43, "mae": -5.94 }, { "label": "+20 sessions", "status": "pending", "return": null, "reference_text": "", "price": null, "price_basis": null, "observation_date": null, "updated": "", "mfe": null, "mae": null }, { "label": "+25 sessions", "status": "pending", "return": null, "reference_text": "", "price": null, "price_basis": null, "observation_date": null, "updated": "", "mfe": null, "mae": null }, { "label": "+30 sessions", "status": "pending", "return": null, "reference_text": "", "price": null, "price_basis": null, "observation_date": null, "updated": "", "mfe": null, "mae": null } ], "market_comparison": { "schema_version": "public-market-comparison.v1", "publication_key": "20261009:midday:TEVA", "status": "awaiting_regular_close", "methodology": { "price_phase": "official_regular_close", "candidate_return": "close_price / previous_regular_close - 1", "benchmark_return": "close_price / previous_regular_close - 1", "return_from_publication_baseline": "regular_close_price / same_instrument_baseline_price - 1; only when the baseline quote timestamp is at or after publication and before the regular close", "excess": "candidate_session_return_pct - benchmark_session_return_pct", "alignment": "same US market day and regular-close phase", "session_range": { "start": 0, "end": 30 }, "missing_data": "unavailable; never filled from another date" }, "sessions": [], "coverage": { "sessions_observed": 0, "sessions_complete": 0, "sessions_partial": 0 }, "updated_at": null }, "candidates": [ { "symbol": "HUM", "name": "Humana Inc.", "exchange": "NYSE", "tradingview_url": "https://es.tradingview.com/chart/?symbol=NYSE%3AHUM&interval=60", "score": 4, "price": 435.21, "change": 12.42, "volume": 2476816, "avg_volume_3m": 1260607, "volume_ratio": 1.96, "rsi": 70.24, "ema_trend": "400.61 > 394.58 > 392.01", "position_52w_pct": 95.26, "vwap": 440.3, "vwap_distance_pct": null, "vwap_state": "below", "facts": [ "The ratings thesis applies to the narrative episode. The linked N0 and narrative records are one ticker-day case, not two independent confirmations.", "The supplied ratings evidence said 95% of Humana's Medicare Advantage members would be in plans rated at least four stars for 2027, including 42% in 4.5-star plans; the stated payment-year effect was 2028.", "The captured N0 change was +12.42%. At the 11:17 ET intraday observation, price was $435.66, below the $440.30 session VWAP, with a downward intraday trend and range position of 0.257.", "Over 20 sessions HUM returned 6.08%, versus 3.22% for the healthcare proxy, an excess of 2.86 percentage points.", "The active model's session-15 positive-return estimate was 0.521, with adverse-MAE quantiles of -17.922386% at p10 and -6.897027% at p50. The prepared SEC context is not point-in-time validated." ], "role": "alternative", "selected": false, "reason": "not_selected" }, { "symbol": "DNA", "name": "Ginkgo Bioworks Holdings, Inc.", "exchange": "NYSE", "tradingview_url": "https://es.tradingview.com/chart/?symbol=NYSE%3ADNA&interval=60", "score": null, "price": 13.2535, "change": null, "volume": 2907166.0, "avg_volume_3m": 1796431.0, "volume_ratio": 1.62, "rsi": 67.1, "ema_trend": "12.08 > 10.75 > 9.29", "position_52w_pct": 72.94, "vwap": 12.65, "vwap_distance_pct": null, "vwap_state": "above", "facts": [ "The quote was up 17.2% on 1.62 times average volume and above the $12.65 session VWAP at $13.29.", "Over 20 sessions DNA returned 96.59%, versus 3.22% for the healthcare proxy; the packet does not connect the reported lab programs to recognized revenue.", "The prepared SEC snapshot for the quarter ended March 31 reported revenue of $19.474 million, down 49.06% year over year, and a net loss of $82.587 million. The snapshot is context-only and is not point-in-time validated.", "The active model's session-15 positive-return estimate was 0.446, with adverse-MAE quantiles of -32.812187% at p10 and -13.103389% at p50. These estimates are contextual and show a wider adverse range." ], "role": "alternative", "selected": false, "reason": "not_selected" } ], "news": [ { "title": "SEC 8-K filing", "url": "https://www.sec.gov/Archives/edgar/data/818686/000119312526393116/d155511d8k.htm" }, { "title": "SEC 8-K filing", "url": "https://www.sec.gov/Archives/edgar/data/818686/000119312526390562/d503082d8k.htm" }, { "title": "SEC 8-K filing", "url": "https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/d81245d8k.htm" }, { "title": "Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript", "url": "https://finnhub.io/api/news?id=19ab9ba0ce811c9ffb7e276b9f4b4afb6d73fa0f44d7ef50cbfac316810f264b" } ], "transcript_url": null, "initial_transcript_anchor": "transcript-entry-0c672fb668412abef4004761181dbb082253f878c99a6831cd89a0b4ed4646d3", "chart_url": null, "secondary_chart_url": null, "forecast_chart_url": null, "methodology_url": "https://trydingday.com/methodology/", "track_record_url": "https://trydingday.com/track-record/", "market_timezone": "America/New_York" } }